The native GnRH decapeptide that earned a Nobel Prize and controls the entire reproductive axis — FDA-approved as both a diagnostic test and a fertility treatment, now quietly repurposed by peptide communities as an hCG alternative for testosterone maintenance

Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH), identical in every amino acid to the decapeptide secreted by the hypothalamus to govern the entire reproductive endocrine axis. Its discovery — and the discovery of GnRH itself — earned Andrew Schally and Roger Guillemin the Nobel Prize in Physiology or Medicine in 1977, one of the few Nobel Prizes shared by rival researchers who raced each other to the same molecule.

The pharmacology of gonadorelin is defined by one of the most important paradoxes in endocrinology: pulsatile delivery stimulates the reproductive axis, while continuous delivery shuts it down. Give GnRH in pulses every 90 minutes and it restores testosterone, ovulation, and fertility. Give it continuously and it causes chemical castration. This single principle — the pulse-versus-continuous paradox — is the foundation of an entire drug class (GnRH agonists like leuprolide and triptorelin) and explains why gonadorelin can be used both to start and to stop reproduction.

The FDA approved gonadorelin as Factrel (1978, diagnostic) and Lutrepulse (1990, pulsatile pump for hypothalamic amenorrhea). Both are now discontinued in the US but remain available internationally and through compounding pharmacies. In the peptide community, gonadorelin has found a second life as a subcutaneous injection for testosterone maintenance during TRT — a use that is mechanistically plausible but has never been tested in a controlled trial.

Quick Facts: Gonadorelin at a Glance

What Is Gonadorelin?

Pronunciation: gon-ad-oh-REL-in

In 1971, two rival laboratories — Andrew Schally's at Tulane University and Roger Guillemin's at the Salk Institute — independently isolated and characterized a ten-amino-acid peptide from pig and sheep hypothalami. The molecule was gonadotropin-releasing hormone, the signal that tells the pituitary gland to produce the hormones that drive the entire reproductive system. Six years later, both men shared the Nobel Prize for the discovery. It remains one of science's most celebrated rivalries: Schally and Guillemin processed hundreds of thousands of animal brains, worked for over a decade, and published their results within months of each other.

Gonadorelin is the synthetic form of that molecule — identical in every amino acid to the GnRH your hypothalamus secretes every 90 minutes or so, in precisely timed pulses, to keep your reproductive axis running. It is not an analog, not a modification, not a derivative. It is the hormone itself, made in a laboratory instead of a brain.

What makes gonadorelin pharmacologically fascinating — and what distinguishes it from every other peptide in this cluster — is the pulse-versus-continuous paradox. Give it in pulses, and it stimulates fertility. Give it continuously, and it causes chemical castration. No other peptide hormone exhibits this dual pharmacology so dramatically, and understanding why it works this way is essential to understanding gonadorelin, its derivatives, and the entire GnRH drug class.

Origins and Discovery

The Great Hypothalamic Hormone Hunt

The story of GnRH begins with a hypothesis that most scientists in the 1950s considered unlikely: that the hypothalamus — a small structure at the base of the brain — controlled the pituitary gland through chemical messengers rather than direct neural connections. Geoffrey Harris proposed this "neurohumoral hypothesis" in the 1940s, suggesting that the hypothalamus secreted releasing factors into a portal blood system that carried them to the anterior pituitary.

Proving Harris right required isolating those factors from brain tissue — a project of staggering scale. Schally's lab at Tulane processed over 300,000 pig hypothalami. Guillemin's lab at the Salk Institute used approximately 500,000 sheep hypothalami. Both teams worked for more than a decade before they had enough purified material to determine the structure of any releasing hormone.

The Discovery Race

Schally's group published the structure of GnRH — a decapeptide with pyroglutamic acid at the N-terminus and an amidated glycine at the C-terminus — in 1971. Guillemin's group confirmed the sequence independently. The molecule was small (only 10 amino acids, 1,182 Da) but its function was enormous: it was the single signal that controlled LH and FSH secretion, and through them, all downstream sex steroid production and reproductive function.

The 1977 Nobel Prize in Physiology or Medicine was shared three ways: Schally and Guillemin for the hypothalamic releasing hormones, and Rosalyn Yalow for the development of radioimmunoassay — the technology that made measuring these hormones possible.

From Discovery to Drug

Synthetic gonadorelin was available almost immediately after sequencing. The Factrel diagnostic test — an IV bolus of 100 mcg used to assess pituitary function — was FDA-approved in 1978. The therapeutic breakthrough came with pulsatile delivery: Knobil's group demonstrated in 1980 that the hypothalamic GnRH pulse generator fires in discrete episodes, and that mimicking this pulsatile pattern with exogenous GnRH could restore fertility in patients with hypothalamic GnRH deficiency. Lutrepulse (pulsatile SC pump) was FDA-approved in 1990.

Both products were eventually discontinued in the US — not because of safety concerns, but because they were commercially marginalized by simpler gonadotropin therapies (hCG, hMG) for fertility and by long-acting GnRH agonists for suppression. Gonadorelin itself remains available through compounding pharmacies.

Mechanism of Action

The GnRH Pulse Generator

Your hypothalamus contains a network of approximately 1,000–2,000 GnRH neurons that fire in synchronized bursts — the GnRH pulse generator. Every 60–120 minutes, this network releases a bolus of GnRH into the hypothalamic-pituitary portal blood system. Each pulse travels to the anterior pituitary, where it binds GnRH receptors (GnRHR) on gonadotrope cells and triggers a burst of LH and FSH release.

The pulse frequency is not random — it encodes information. Faster pulses (every 60 minutes) favor LH secretion. Slower pulses (every 120–240 minutes) favor FSH secretion. This frequency-dependent coding is how the hypothalamus fine-tunes the LH:FSH ratio across the menstrual cycle and maintains spermatogenesis in men.

The GnRH Receptor: A Unique GPCR

GnRHR is unusual among G protein-coupled receptors in that it lacks an intracellular C-terminal tail. This means it does not undergo the rapid β-arrestin-mediated desensitization that most GPCRs use to self-regulate. Instead, GnRHR desensitization occurs through receptor internalization — the entire receptor is pulled into the cell and degraded. This slower desensitization mechanism is why continuous GnRH exposure eventually causes profound suppression: the cell simply runs out of surface receptors.

When a GnRH pulse arrives, GnRHR couples to Gq/11 → activates phospholipase C → generates IP3 and DAG → mobilizes intracellular calcium → activates protein kinase C → induces LH-β and FSH-β gene transcription and hormone release. The calcium mobilization is what triggers the immediate burst of stored LH/FSH granules; the gene transcription replenishes the stores between pulses.

The Pulse-Versus-Continuous Paradox

This is the central pharmacological principle of gonadorelin and the entire GnRH drug class:

Pulsatile GnRH (every 60–120 minutes): Each pulse occupies GnRH receptors briefly. Between pulses, receptors recycle to the cell surface and are replenished. The gonadotrope maintains a healthy population of surface receptors, responds to each new pulse, and sustains normal LH/FSH secretion. This is the normal physiological state — and it is what pulsatile gonadorelin therapy mimics.

Continuous GnRH (steady-state exposure): Sustained receptor occupation overwhelms the recycling mechanism. Receptors are internalized faster than they can be replaced. Within 1–2 weeks, surface receptor density drops by >90%. Gonadotrope cells can no longer respond to GnRH. LH and FSH fall to undetectable levels. Downstream sex steroids collapse to castrate range (testosterone <50 ng/dL, estradiol <20 pg/mL).

This paradox explains why every GnRH agonist drug on the market — leuprolide, triptorelin, nafarelin, goserelin — works by suppression. These analogs are designed for sustained receptor activation: depot formulations that maintain continuous exposure for weeks to months. The initial "flare" (a surge of LH/FSH) gives way to desensitization and chemical castration.

The GnRH Stimulation Test (Factrel Test)

The diagnostic application of gonadorelin exploits the immediate gonadotrope response to an acute GnRH pulse:

1. Baseline LH and FSH blood draw 2. IV bolus: 100 mcg gonadorelin 3. Serial draws at 15, 30, 45, 60, and 120 minutes

Interpretation: - Normal response: LH rises 3–6× from baseline within 15–30 minutes - Exaggerated response: LH rises >10× — suggests hypothalamic GnRH deficiency with intact pituitary. The gonadotropes have been deprived of GnRH stimulation, so surface receptors are upregulated and hyper-responsive to exogenous GnRH - Flat response: LH rises <2× — suggests pituitary gonadotrope failure. The cells are damaged and cannot respond regardless of receptor status

This test distinguishes hypothalamic from pituitary causes of hypogonadotropic hypogonadism — a critical diagnostic distinction that determines whether the patient needs GnRH replacement (hypothalamic) or gonadotropin replacement (pituitary).

Pulsatile GnRH Therapy (Lutrepulse)

For patients with isolated hypothalamic GnRH deficiency — Kallmann syndrome, functional hypothalamic amenorrhea, or idiopathic hypogonadotropic hypogonadism — pulsatile gonadorelin restores the entire downstream cascade:

• A portable microinfusion pump delivers SC or IV boluses of 25–200 mcg every 90–120 minutes
• Pituitary gonadotropes resume normal LH/FSH pulsatility
• In women: follicular development → ovulation → potential conception
• In men: spermatogenesis restarts → testicular volume increases → testosterone normalizes

The advantage over direct gonadotropin therapy (hMG + hCG) is physiological fidelity: pulsatile GnRH lets the pituitary regulate itself, producing more physiological LH/FSH ratios and lower rates of ovarian hyperstimulation.

Key Research Areas and Studies

Pulsatile GnRH for Female Infertility

The landmark studies establishing pulsatile gonadorelin for hypothalamic amenorrhea date to the early 1980s. Leyendecker et al. (1980, PMID 6771530) demonstrated ovulation induction with a portable GnRH pump in 11 women with hypothalamic amenorrhea — the first proof that exogenous pulsatile GnRH could restore physiological ovulation. Hoffman and Crowley (1982, PMID 7044640) expanded this to 28 patients, achieving ovulation in 93% of treatment cycles with a pregnancy rate per cycle comparable to natural conception rates.

The key advantage over gonadotropin therapy (Santoro et al. 1986, PMID 3093614) was lower rates of ovarian hyperstimulation and multiple pregnancies — because pulsatile GnRH allows the pituitary's endogenous negative feedback to regulate follicle recruitment, rather than bypassing feedback entirely with exogenous gonadotropins. Twin rates with pulsatile GnRH (~12–15%) were substantially lower than with gonadotropin protocols of that era (~20–30%).

Pulsatile GnRH for Male Hypogonadotropic Hypogonadism

Martin et al. (1993, PMID 8468086) demonstrated spermatogenesis induction with pulsatile GnRH in 9 men with idiopathic hypogonadotropic hypogonadism. The most comprehensive modern data comes from Dwyer et al. (2019, PMID: PMC6775549), a retrospective comparison of 316 men: those treated with pulsatile GnRH achieved greater testicular growth and higher sperm concentrations than those treated with hCG/hMG, with the advantage most pronounced in men with more severe GnRH deficiency.

Boehm et al. (2015, PMID 26417369) reported a multicenter retrospective of 121 men with congenital hypogonadotropic hypogonadism treated with pulsatile GnRH, achieving sperm in >70% — a rate comparable to gonadotropin therapy but with faster onset and fewer monitoring requirements.

GnRH Pulse Frequency Physiology

Chan et al. (2003, PMID 12574222) provided elegant controlled data on how GnRH pulse frequency determines the LH:FSH ratio in humans. In 10 men given pulsatile IV GnRH at varying frequencies, faster pulses (every 60 minutes) increased the LH:FSH ratio, while slower pulses (every 180 minutes) shifted the ratio toward FSH dominance. This confirmed the frequency-coding hypothesis and explained how the hypothalamus adjusts the gonadotropin balance across physiological states.

Liu et al. (2017, PMID: PMC5676428) meta-analyzed outcomes of pulsatile GnRH versus gonadotropin therapy for male spermatogenesis induction (580 patients), finding comparable overall efficacy with a suggestion of faster time to sperm appearance in the GnRH group.

Claims vs. Evidence

We currently don’t have any vetted partners for this compound. Check back soon.

The Human Evidence Landscape

Landmark Trial: Leyendecker et al. (1980) — First Pulsatile GnRH Ovulation Induction

Design: Prospective, uncontrolled. 11 women with hypothalamic amenorrhea. Intervention: Pulsatile IV GnRH via portable pump, 5–20 mcg per pulse, every 90 minutes. Key finding: Ovulation documented in 9 of 11 women (82%). First demonstration that exogenous pulsatile GnRH restores physiological ovulation. Limitations: Small, uncontrolled. No comparison group. IV route (later replaced by SC). Significance: Proof-of-concept that launched an entire therapeutic approach. PMID 6771530

Hoffman and Crowley (1982) — Pulsatile GnRH Outcomes in Hypothalamic Amenorrhea

Design: Prospective case series. 28 women, 80 treatment cycles. Intervention: Pulsatile SC GnRH, 75 mcg per pulse, every 90 minutes. Key finding: Ovulation in 93% of cycles. Conception rate per cycle comparable to normal fertility. Limitations: Not randomized or controlled. Single center (Massachusetts General Hospital). Significance: Established pulsatile GnRH as a viable clinical therapy. PMID 7044640

Santoro et al. (1986) — GnRH vs Gonadotropins for Ovulation Induction

Design: Controlled comparison. 25 women with hypothalamic amenorrhea. Intervention: Pulsatile GnRH pump vs standard hMG/hCG gonadotropin protocol. Key finding: Comparable ovulation rates. GnRH group had lower rates of ovarian hyperstimulation and fewer multiple follicles. Limitations: Small sample. Non-randomized comparison (allocation based on patient preference in some cases). Significance: First demonstration of the safety advantage of pulsatile GnRH over gonadotropins. PMID 3093614

Martin et al. (1993) — Pulsatile GnRH for Male Spermatogenesis

Design: Prospective. 9 men with idiopathic hypogonadotropic hypogonadism. Intervention: Pulsatile SC GnRH, every 120 minutes, 25–600 ng/kg per pulse. Key finding: Spermatogenesis induced in all 9 men. Testosterone normalized. Testicular volume increased. Limitations: Very small sample. No control group. Significance: Extended pulsatile GnRH therapy to male fertility. PMID 8468086

Boehm et al. (2015) — Multicenter Retrospective: Pulsatile GnRH in Congenital HH

Design: Multicenter retrospective analysis. 121 men with congenital hypogonadotropic hypogonadism. Intervention: Pulsatile GnRH pump therapy (various centers, various protocols). Key finding: >70% achieved spermatogenesis. Time to sperm appearance varied by severity of GnRH deficiency and prior cryptorchidism history. Limitations: Retrospective, heterogeneous protocols across centers. No standardized dosing. Significance: Largest multicenter dataset confirming pulsatile GnRH efficacy in men. PMID 26417369

Dwyer et al. (2019) — GnRH vs Gonadotropins in Male IHH

Design: Retrospective comparison. 316 men: 81 pulsatile GnRH, 235 gonadotropin therapy. Intervention: Pulsatile GnRH pump vs combined hCG/hMG. Key finding: GnRH group achieved significantly greater testicular growth and higher sperm concentrations. Advantage most pronounced in men with more severe GnRH deficiency (lower baseline testicular volume, absent puberty). Limitations: Retrospective. Selection bias (more severe cases may have been preferentially offered GnRH). Different time periods of treatment. Significance: Strongest evidence that pulsatile GnRH may be superior to gonadotropins in severe male HH. PMID: PMC6775549

Pitteloud et al. (2008) — GnRH Stimulation Test Accuracy

Design: Prospective diagnostic study. 85 men (constitutional delay vs true GnRH deficiency). Intervention: 100 mcg IV gonadorelin bolus with serial LH/FSH sampling. Key finding: GnRH stimulation test reliably distinguishes constitutional delay from permanent hypogonadotropic hypogonadism, though some overlap exists in the borderline range. Limitations: Cross-sectional. Some patients required repeated priming for accurate classification. Significance: Validated the Factrel test as a diagnostic tool in the modern era. PMID 18782864

Safety, Risks, and Limitations

Well-Established Adverse Effects (Pulsatile Pump)

The pulsatile GnRH pump has decades of safety data. The most significant risks are related to the therapeutic effect itself — restoring fertility — rather than to drug toxicity:

Ovarian hyperstimulation syndrome (OHSS): Rare with pulsatile GnRH (estimated 1–3% of cycles), significantly less frequent than with gonadotropin protocols. When it occurs, it is typically mild (ovarian enlargement, pelvic discomfort) rather than severe. The lower OHSS risk is a primary advantage of pulsatile GnRH over gonadotropins.

Multiple pregnancies: Twin rate approximately 12–15%. Triplet or higher-order multiples are rare. This is substantially lower than gonadotropin-stimulated cycles of the same era.

Injection site reactions: SC infusion site erythema, induration, and occasionally local infection with prolonged pump use. Managed with site rotation.

Anti-GnRH antibodies: Reported rarely with prolonged pulsatile therapy. Can reduce treatment efficacy. Not associated with systemic autoimmune effects.

Diagnostic (Factrel Test) Adverse Effects

The single IV bolus is well-tolerated. Reported effects include headache (~5%), nausea (~2%), flushing (~2%), abdominal discomfort (~2%). Anaphylactic reactions are extremely rare (<0.1%) but have been reported.

Community-Use Safety Considerations

No controlled safety data exists for the SC bolus protocol used in TRT/PCT contexts. Key concerns:

Paradoxical suppression risk: If injection frequency is too high — producing near-continuous GnRH receptor occupation — the intended stimulatory effect could reverse into suppressive desensitization. The 2–4 minute half-life of gonadorelin provides a natural safety margin (each injection clears rapidly), but multiple daily injections or very high doses could narrow this margin.

SC pharmacokinetics differ from IV and pump delivery. SC absorption is slower than IV, which may extend the effective pulse duration. Whether this extension is clinically significant — or whether it moves the pharmacokinetics closer to continuous exposure territory — has not been studied.

Compounding pharmacy quality. All US gonadorelin comes from 503A or 503B compounding pharmacies. Potency, sterility, and stability vary by compounder. No centralized pharmacovigilance monitors adverse events from compounded gonadorelin.

Legal and Regulatory Status

Gonadorelin occupies an unusual regulatory position: it is an FDA-approved drug with no approved product currently on the US market.

FDA status: Approved. Factrel (diagnostic, 1978) and Lutrepulse (therapeutic pulsatile pump, 1990) both received FDA approval. Both have been discontinued — Factrel by Ayerst/Pfizer, Lutrepulse by Ferring — for commercial reasons, not safety concerns.

Compounding pharmacy availability: Gonadorelin is available through both 503A (patient-specific) and 503B (outsourcing facility) compounding pharmacies. It is commonly prescribed by fertility specialists, urologists, and anti-aging medicine practitioners. No DEA scheduling.

International availability: Marketed under various brand names outside the US (Cystorelin in veterinary use). Available by prescription in multiple countries.

WADA status: Prohibited at all times under class S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Specifically listed for its LH-releasing activity. Athletes subject to anti-doping testing cannot use gonadorelin.

FTC/advertising considerations: Because it is an approved drug, claims about gonadorelin must be accurate and not extend beyond the evidence base. Compounding pharmacies face additional FTC scrutiny when marketing compounded versions of approved drugs.

Research Protocols and Formulation Considerations

Formulation and Storage

Gonadorelin acetate is supplied as a lyophilized powder for reconstitution, typically at 2 mg/mL concentration. Standard reconstitution uses bacteriostatic water or sterile saline.

Storage: Lyophilized powder stored at 2–8°C (36–46°F). After reconstitution, refrigerated at 2–8°C and used within 14–28 days depending on compounder specifications. Protect from light.

Stability considerations: Gonadorelin is susceptible to degradation by aminopeptidases in solution. Reconstituted vials should not be stored at room temperature. The pyroglutamic acid N-terminus provides some protection against aminopeptidase degradation compared to free glutamic acid, but the C-terminal amide bond is vulnerable to carboxypeptidase activity.

Administration Considerations

Diagnostic (Factrel test): Single IV bolus of 100 mcg. Requires IV access and serial blood draws at timed intervals. Performed in clinic.

Therapeutic pulsatile pump: SC or IV microinfusion pump delivering 5–200 mcg per pulse (dose individualized) every 90–120 minutes. Pump programming and monitoring require specialized endocrine clinic expertise. Patients learn self-care of the pump and infusion site.

Community SC injection protocol: Typical compounding pharmacy vials are 2 mg/mL or 5 mg/mL. Users draw individual doses (100–200 mcg) and inject SC in the abdominal subcutaneous tissue. 29–31 gauge insulin syringes are standard.

Dosing in Published Research

The following table summarizes dosing protocols for Gonadorelin as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.

Diagnostic Dosing

The Factrel test protocol is standardized:

Therapeutic Dosing (Pulsatile Pump)

Dosing in Self-Experimentation Communities

Community Dosing Protocol: hCG Alternative for TRT

The most common community use is SC gonadorelin as a substitute for hCG during testosterone replacement therapy. Typical reported protocol:

Community Rationale

Community users hypothesize that each SC injection of gonadorelin approximates a single GnRH pulse. Because the half-life is 2–4 minutes (IV), even SC absorption would clear within approximately 30–60 minutes, theoretically preventing the continuous exposure that would cause desensitization. At 2–3 injections per week, the pituitary would receive discrete stimulatory pulses with long recovery periods between them.

What the Evidence Cannot Confirm

No controlled study has tested whether: 1. SC bolus pharmacokinetics actually produce a pulse-like receptor occupation profile 2. 2–3 injections per week is sufficient to maintain testicular function 3. This protocol prevents testicular atrophy as effectively as hCG 4. Long-term use at these doses maintains pituitary sensitivity

The community's experience is anecdotal. Reports suggest that gonadorelin maintains LH levels and testicular volume in some users, but selection bias (users who do not respond may stop reporting) limits the reliability of these reports.

Combination Stacks

Research into Gonadorelin combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining Gonadorelin with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

Gonadorelin is synthetic GnRH — the native decapeptide that governs the entire reproductive endocrine axis. Its discovery earned the 1977 Nobel Prize, and its pharmacology introduced one of the most important paradoxes in endocrinology: pulsatile delivery stimulates reproduction, while continuous delivery shuts it down.

The evidence for gonadorelin's approved indications — diagnostic pituitary testing and pulsatile pump fertility therapy — is deep and consistent. Multiple studies totaling over 600 patients demonstrate that pulsatile GnRH restores ovulation in >90% of women with hypothalamic amenorrhea and induces spermatogenesis in >70% of men with hypogonadotropic hypogonadism. The largest comparative study (Dwyer 2019, n=316) suggests pulsatile GnRH may be superior to gonadotropin therapy for the most severe male cases.

The community use — SC injection as an hCG alternative during TRT — has a sound mechanistic basis but no controlled evidence. Each injection should approximate a single GnRH pulse, but whether 2–3 injections per week is sufficient to maintain testicular function has never been formally tested. This is an evidence gap, not a safety alarm — but it is a gap that should be acknowledged honestly.

Verdict Recapitulation

For an FDA-approved drug whose mechanism is fully characterized, whose clinical efficacy is demonstrated across multiple indications, and whose safety profile reflects decades of pharmacovigilance, "Strong Foundation" is warranted. The community repurposing introduces an evidence gap for one specific use, but it does not diminish the compound's overall standing. Gonadorelin is the molecule that started an entire drug class — and it remains the most elegant demonstration of pulsatile pharmacology in endocrinology.

For readers considering Gonadorelin, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source Gonadorelin

Further Reading and Resources

If you want to go deeper on Gonadorelin, the evidence landscape for sexual health & hormonal peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Sexual Health & Hormonal Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: Gonadorelin — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Schally AV, et al. (1971). "Isolation and properties of the FSH and LH-releasing hormone." Biochem Biophys Res Commun, 43(2), 393-399
2. Belchetz PE, et al. (1978). "Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone." Science, 202(4368), 631-633. PMID 362125
3. Leyendecker G, et al. (1980). "Induction of ovulation with chronic intermittent (pulsatile) administration of LH-RH in women with hypothalamic amenorrhea." J Reprod Fertil, 59(2), 405-411. PMID 6771530
4. Hoffman AR, Crowley WF Jr. (1982). "Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone." N Engl J Med, 307(20), 1237-1241. PMID 7044640
5. Santoro N, et al. (1986). "Comparison of gonadotropin-releasing hormone and gonadotropins for ovulation induction in hypothalamic amenorrhea." Fertil Steril, 46(5), 869-875. PMID 3093614
6. Martin K, et al. (1993). "Physiologic roles of pulsatile and tonic gonadotropin-releasing hormone secretion in the induction of male puberty." J Neuroendocrinol, 5(4), 365-371. PMID 8468086
7. Chan YM, et al. (2003). "GnRH pulse frequency determines differential gonadotropin secretion." J Clin Endocrinol Metab, 88(10), 4697-4702. PMID 12574222
8. Pitteloud N, et al. (2008). "The relative role of gonadal sex steroids and gonadotropin-releasing hormone pulse frequency in the regulation of follicle-stimulating hormone secretion in men." J Clin Endocrinol Metab, 93(7), 2686-2692. PMID 18782864
9. Boehm U, et al. (2015). "European Consensus Statement on congenital hypogonadotropic hypogonadism." Nat Rev Endocrinol, 11(9), 547-564. PMID 26417369
10. Liu PY, et al. (2017). "Comparison of gonadotropin-releasing hormone with gonadotropins for spermatogenesis induction in hypogonadotropic hypogonadism." J Clin Endocrinol Metab. PMID: PMC5676428
11. Dwyer AA, et al. (2019). "Pulsatile GnRH therapy for male hypogonadotropic hypogonadism." Eur J Endocrinol, 181(4), 397-404. PMID: PMC6775549

---